Repository logo
 
Publication

The effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions

2023-03Journal article Open access
Simple item page
dc.contributor.authorSimonaviciute, Dovile
dc.contributor.authorGrzybowski, Andrzej
dc.contributor.authorLança, Carla
dc.contributor.authorPang, Chi Pui
dc.contributor.authorGelzinis, Arvydas
dc.contributor.authorZemaitiene, Reda
dc.date.accessioned2023-04-20T10:56:01Z
dc.date.available2023-04-20T10:56:01Z
dc.date.issued2023-03
dc.description.abstractMyopia is the most common ocular disorder worldwide with an increasing prevalence over the past few decades. It is a refractive error associated with excessive growth of the eyeball. Individuals with myopia, especially high myopia, are prone to develop sight-threatening complications. Currently, atropine is the only drug that is used to slow myopia progression in clinical practice. However, there are still areas of uncertainty such as treatment strategy, optimal concentration when considering the risk-benefit ratio, and active treatment period. Since the prevalence of myopia is much higher in Asian countries, most of the research on myopia control has been conducted in Asia. Data on the efficacy and tolerability of atropine eye drops in the non-Asian population remains limited. In this review, we summarize the results of published clinical trials on the effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions. The efficacy was evaluated by the mean change in spherical equivalent (SE) or axial length (AL). The tolerability of atropine eye drops was analyzed based on patients' complaints and adverse events. The results of this review suggest that 0.01% atropine eye drops are effective in non-Asian regions achieving fewer side effects compared to 0.5% concentration.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationSimonaviciute D, Grzybowski A, Lança C, Pang CP, Gelzinis A, Zemaitiene R. The effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions. J Clin Med. 2023;12(6):2314.pt_PT
dc.identifier.doi10.3390/jcm12062314pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.21/15915
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.relation.publisherversionhttps://www.mdpi.com/2077-0383/12/6/2314pt_PT
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/pt_PT
dc.subjectOphthalmologypt_PT
dc.subjectMyopiapt_PT
dc.subjectAtropine eye dropspt_PT
dc.subjectMyopia controlpt_PT
dc.subjectMyopia progressionpt_PT
dc.subjectMyopia treatmentpt_PT
dc.titleThe effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regionspt_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.issue6pt_PT
oaire.citation.startPage2314pt_PT
oaire.citation.titleJournal of Clinical Medicinept_PT
oaire.citation.volume12pt_PT
person.familyNameLança
person.givenNameCarla
person.identifier.ciencia-id601A-6412-BF2F
person.identifier.orcid0000-0001-9918-787X
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication0320b455-ee19-4670-8bf2-10dce9de1bec
relation.isAuthorOfPublication.latestForDiscovery0320b455-ee19-4670-8bf2-10dce9de1bec

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
The effectiveness and tolerability of atropine eye drops for myopia control in non-Asian regions.pdf
Size:
1 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ESTeSL - Artigos